Consensus EPS · Q1 2026
$1.86
Consensus revenue · Q1 2026
$2.1B
Analysts
18
Last reported
Apr 28, 2026
Analyst consensus
Based on estimates from 18 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $2.1B | $2.1B | $2.1B |
| EPS | $1.84 | $1.86 | $1.93 |
| EBITDA | $506.3M | $546.2M | $554.2M |
| EBIT | $252.1M | $272M | $276M |
| Net income | $359.3M | $365.2M | $375M |
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q1 2026 | $2.1B | $2.1B | +0.8% | $2.09 | $1.87 | +12.0% |
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
No community consensus
No TickerLeague members predicted Zimmer Biomet Holdings (ZBH) Q1 2026 before it reported.
Analyst price target
Based on price targets from 0 analysts.
| Low | Consensus | Median | High | Current | Upside |
|---|---|---|---|---|---|
| $83.00 | $96.33 | $93.00 | $120.00 | $87.97 | +9.5% |
Upside calculated vs most recent trading price of $87.97.
Analyst ratings
Consensus: Hold — based on 42 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 28, 2026 | Citigroup | maintain | Neutral | Neutral |
| Apr 29, 2026 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Apr 29, 2026 | Truist Securities | maintain | Hold | Hold |
| Apr 29, 2026 | Stifel | maintain | Buy | Buy |
| Apr 29, 2026 | JP Morgan | maintain | Neutral | Neutral |
| Apr 29, 2026 | Citizens | maintain | Market Outperform | Market Outperform |
| Apr 29, 2026 | Citigroup | maintain | Neutral | Neutral |
| Apr 29, 2026 | Barclays | maintain | Underweight | Underweight |
| Mar 23, 2026 | BTIG | downgrade | Buy | Neutral |
| Feb 12, 2026 | Barclays | maintain | Underweight | Underweight |
Frequently asked questions
Zimmer Biomet Holdings (ZBH) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation